J T Mettetal
Overview
Explore the profile of J T Mettetal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
94
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collins T, Hattersley M, Yates J, Clark E, Mondal M, Mettetal J
CPT Pharmacometrics Syst Pharmacol
. 2017 Apr;
6(6):357-364.
PMID: 28378926
In this work, we evaluate the potential risk of thrombocytopenia in man for a BRD4 inhibitor, AZD5153, based on the platelet count decreases from a Han Wistar rat study. The...
2.
Yang K, Battista C, Woodhead J, Stahl S, Mettetal J, Watkins P, et al.
Clin Pharmacol Ther
. 2017 Jan;
101(4):501-509.
PMID: 28074467
Elevations in serum bilirubin during drug treatment may indicate global liver dysfunction and a high risk of liver failure. However, drugs also can increase serum bilirubin in the absence of...
3.
Collins T, Bergenholm L, Abdulla T, Yates J, Evans N, Chappell M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2015 Jul;
4(3):e00018.
PMID: 26225237
Systems pharmacology modeling and pharmacokinetic-pharmacodynamic (PK/PD) analysis of drug-induced effects on cardiovascular (CV) function plays a crucial role in understanding the safety risk of new drugs. The aim of this...
4.
Venkatakrishnan K, Friberg L, Ouellet D, Mettetal J, Stein A, Troconiz I, et al.
Clin Pharmacol Ther
. 2015 Feb;
97(1):37-54.
PMID: 25670382
Despite advances in biomedical research that have deepened our understanding of cancer hallmarks, resulting in the discovery and development of targeted therapies, the success rates of oncology drug development remain...